OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
June 18, 2021
GlaxoSmithKline and iTeos Therapeutics enter into a development and commercialization collaboration worth up to $2.08 billion for a new therapeutic anti-cancer mAb candidate.
June 08, 2021
FDA has granted fast track designation to a GLP-1/glucagon dual agonist in development by Boehringer Ingelheim and Zealand Pharma for the treatment of NASH.
FDA has granted Janssen breakthrough therapy designation for teclistamab, an investigational bispecific antibody under development for treating relapsed or refractory multiple myeloma.
June 07, 2021
FDA has granted accelerated approval to Biogen for Aduhelm (aducanumab), a new mAb treatment for Alzheimer’ disease.
June 02, 2021
The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.
May 03, 2021
Both the European Commission and FDA have granted approval to GlaxoSmithKline’s Jemperli (dostarlimab) for treating endometrial cancer.
April 29, 2021
This new collaboration between Vyant Bio, Ordaōs Bio, and Cellaria mitigates risk in the drug discovery process using artificial intelligence and in-vitro “avatar” clinical trials.
March 15, 2021
A growing pipeline of gene therapy candidates aimed at treating neurodegenerative diseases has prompted new guidance.
January 29, 2021
Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.
January 15, 2021
The collaboration will focus on up to three types of lung and gastrointestinal cancers.